New biopsy technique could spare patients from major surgery
NCT ID NCT01892501
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study looked at whether combining a PET scan with an endoscopic ultrasound-guided needle biopsy can accurately diagnose suspicious lymph nodes in the chest. Researchers tested this less invasive approach in 75 patients who had abnormal lymph nodes on PET scans. The goal was to see if this method could replace more invasive surgical biopsies and help guide treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Endoscopic ultrasound-guided needle biopsy (EUS-guided puncture)
- What this could lead to
- If successful, this approach could provide a less invasive way to diagnose cancer in chest lymph nodes, reducing the need for more risky surgical biopsies.
- What could go wrong
- This is a small, early feasibility study with only 75 participants, so results may not apply to everyone. The technique may not be accurate enough to replace standard methods, and there is a small risk of complications from the biopsy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
75 people
The number who actually took part.
- Started
-
Jan 2013
- Finished
-
Oct 2019
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Any patients who have had PET showing one or more hypermetabolic lymphadenopathy in middle mediastinum and/or lower and/or posterior, and requiring diagnostic certainty for support. 2. PET scans performed in these particulars : * Pre-treatment assessment of thoracic or extra-thoracic malignancies (patients without a history of cancer). * Evaluation of response to treatment referred to oncological. * Suspicion of relapse in patients with a personal history of thoracic or extra-thoracic malignancies. 3. PET, the result is positive : * For above-centimeter lymph node short axis: greater result than or equal to the background hepatic noise. * For sub-centimeter lymph node small axis : greater result than the background hepatic noise 4. Patient with indication of diagnostic procedure surgically (whether realized or not) 5. Lymph node(s) available(s) puncture by EUS esophageal, so for a technically feasible for esophageal puncture (without vascular recusants structures) 6. Age ≥ 18 years. 7. PET scan performed within 6 weeks before EUS 8. Platelets ≥ 70 000/mm3; TP ≥ 60%. 9. Patient of childbearing age with negative pregnancy test and / or a contraception. 10. Patient gave informed consent signed. 11. Patient affiliated to a social security scheme. Exclusion Criteria: * Contra-indication (s) Director (s) to achieve a EUS. * Balance adverse anesthetic (not allowing a general anesthetic). * Esophageal stenosis. * Coagulation disorders. * Pregnant or lactating women. * Unable to undergo medical monitoring test for geographical, social or psychological reasons. * Private patient freedom and major subject of a measure of legal protection or unable to consent.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hypermetabolic lymphadenopathy mediastinum lower, posterior and middle, detected by pet-CT with 18F-FDG (PET) are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Insitut Bergonie
Bordeaux, Grionde, 33076, France